Nifty
:
24273.80
Sensex
:
80334.81
-140.60 (-0.58%)
-411.97 (-0.51%)
Nifty
Sensex
:
:
24273.80
80334.81
-140.60 (-0.58%)
-411.97 (-0.51%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1742.00
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1753.00
  •  1768.35
  •  1736.30
  •  1752.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3421791
  •  59711.59
  •  1960.35
  •  1377.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,23,770.54
  • 37.06
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,16,836.66
  • 0.76%
  • 5.88

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.08%
  • 5.42%
  • FII
  • DII
  • Others
  • 17.96%
  • 17.17%
  • 2.89%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.88
  • 8.11
  • 7.85

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.07
  • 12.82
  • 5.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.76
  • 20.53
  • 42.98

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 38.98
  • 40.42
  • 40.41

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.92
  • 4.46
  • 5.17

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.78
  • 20.72
  • 22.84

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
39.9
47.66
55.07
61.02
P/E Ratio
43.85
36.71
31.77
28.67
Revenue
47758
52989
58713
64073
EBITDA
12987
14921
16945
18567
Net Income
9576
11419
13210
14722
ROA
11.5
12.7
13.2
13.2
P/B Ratio
6.59
5.8
5.09
4.47
ROE
16.01
16.6
16.97
16.76
FCFF
10426.48
9385.88
11788.4
13694.4
FCFF Yield
2.54
2.29
2.87
3.34

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
13,675.46
12,380.70
10.46%
13,291.39
12,192.41
9.01%
12,652.75
11,940.84
5.96%
11,982.90
10,930.67
9.63%
Expenses
9,666.44
9,028.43
7.07%
9,480.52
9,013.03
5.19%
9,045.13
8,611.11
5.04%
8,947.75
8,128.54
10.08%
EBITDA
4,009.02
3,352.27
19.59%
3,810.87
3,179.38
19.86%
3,607.62
3,329.73
8.35%
3,035.15
2,802.13
8.32%
EBIDTM
29.32%
27.08%
28.67%
26.08%
28.51%
27.89%
25.33%
25.64%
Other Income
465.62
374.76
24.24%
482.09
293.61
64.19%
532.55
206.48
157.92%
605.94
373.28
62.33%
Interest
51.51
34.73
48.32%
69.17
49.29
40.33%
61.54
80.88
-23.91%
73.57
92.74
-20.67%
Depreciation
630.56
622.14
1.35%
625.91
632.82
-1.09%
655.13
651.32
0.58%
650.36
671.53
-3.15%
PBT
3,476.40
3,000.35
15.87%
3,597.88
2,790.88
28.92%
3,423.50
2,481.14
37.98%
2,815.52
2,239.69
25.71%
Tax
558.86
432.32
29.27%
567.21
390.10
45.40%
552.25
468.10
17.98%
148.93
222.91
-33.19%
PAT
2,917.54
2,568.03
13.61%
3,030.67
2,400.78
26.24%
2,871.25
2,013.04
42.63%
2,666.59
2,016.78
32.22%
PATM
21.33%
20.74%
22.80%
19.69%
22.69%
16.86%
22.25%
18.45%
EPS
12.10
10.52
15.02%
12.67
9.90
27.98%
11.82
8.43
40.21%
11.06
8.27
33.74%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
51,602.50
48,496.85
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
Net Sales Growth
8.76%
10.51%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
 
Cost Of Goods Sold
10,490.58
10,662.61
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
Gross Profit
41,111.92
37,834.24
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
GP Margin
79.67%
78.01%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
Total Expenditure
37,139.84
35,747.77
32,298.12
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
Power & Fuel Cost
-
760.78
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
560.77
% Of Sales
-
1.57%
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
Employee Cost
-
9,429.06
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
% Of Sales
-
19.44%
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
Manufacturing Exp.
-
2,186.62
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
% Of Sales
-
4.51%
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
General & Admin Exp.
-
5,252.93
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
% Of Sales
-
10.83%
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
Selling & Distn. Exp.
-
5,780.26
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
% Of Sales
-
11.92%
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
Miscellaneous Exp.
-
1,675.51
1,090.75
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
2,236.40
% Of Sales
-
3.45%
2.49%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
EBITDA
14,462.66
12,749.08
11,587.56
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
EBITDA Margin
28.03%
26.29%
26.40%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
Other Income
2,086.20
1,628.24
693.75
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
Interest
255.79
238.47
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
578.99
Depreciation
2,561.96
2,556.64
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
PBT
13,313.30
11,582.21
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
Tax
1,827.25
1,439.45
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
Tax Rate
13.72%
12.98%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
PAT
11,486.05
9,614.79
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
PAT before Minority Interest
11,450.23
9,648.44
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
Minority Interest
-35.82
-33.65
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
PAT Margin
22.26%
19.83%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
PAT Growth
27.64%
12.83%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
 
EPS
47.87
40.07
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94
18.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
63,666.75
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
207.12
Total Reserves
63,426.82
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
Non-Current Liabilities
-2,731.14
-1,997.80
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
Secured Loans
0.00
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
40.69
Unsecured Loans
1.33
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
Long Term Provisions
413.89
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
Current Liabilities
16,983.77
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
Trade Payables
5,653.30
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
Other Current Liabilities
2,716.85
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
Short Term Borrowings
2,844.36
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
Short Term Provisions
5,769.26
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
Total Liabilities
81,358.60
77,224.05
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
Net Block
23,211.38
24,065.44
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
Gross Block
44,283.71
43,099.95
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
Accumulated Depreciation
21,072.33
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
Non Current Assets
37,884.25
37,341.33
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
Capital Work in Progress
5,353.88
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
Non Current Investment
6,441.23
5,451.73
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
Long Term Loans & Adv.
2,784.59
2,757.87
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
Other Non Current Assets
93.17
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
103.94
Current Assets
43,433.11
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
Current Investments
8,584.54
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
Inventories
9,868.29
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
Sundry Debtors
11,249.37
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
Cash & Bank
10,520.68
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
Other Current Assets
3,210.23
745.91
775.01
1,319.11
2,973.02
3,072.69
2,919.93
3,546.51
2,847.64
5,026.16
Short Term Loans & Adv.
2,454.24
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
Net Current Assets
26,449.34
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
Total Assets
81,317.36
77,203.27
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
12,134.98
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
PBT
11,087.89
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
Adjustment
1,554.40
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
Changes in Working Capital
1,062.13
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
Cash after chg. in Working capital
13,704.42
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,569.44
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-690.20
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
Net Fixed Assets
-420.26
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
Net Investments
183.27
2,935.63
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
Others
-453.21
-10,305.34
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
Cash from Financing Activity
-6,710.16
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
Net Cash Inflow / Outflow
4,734.62
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
Opening Cash & Equivalents
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
Closing Cash & Equivalent
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
265.36
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
123.49
ROA
12.17%
11.88%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
ROE
16.13%
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
ROCE
17.60%
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
Fixed Asset Turnover
1.11
1.07
1.81
1.74
1.78
1.92
1.99
1.29
1.34
1.79
Receivable days
85.38
91.17
53.09
54.88
56.22
54.10
53.53
83.25
76.12
48.20
Inventory Days
76.70
80.83
48.68
50.10
48.40
47.84
48.88
78.98
77.46
57.99
Payable days
194.01
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
52.05
Cash Conversion Cycle
-31.93
-2.10
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
Total Debt/Equity
0.04
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
0.35
Interest Cover
47.50
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56
12.06

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Sun Pharmaceutical Industries’ arm recalls around 13,700 bottles of Gabapentin capsules
    14th Apr 2025, 11:43 AM

    Sun Pharmaceutical Industries Inc is recalling the affected lot due to 'Cross Contamination'

    Read More
  • US court lifts restrictions on Sun Pharma launching autoimmune disorder drug
    11th Apr 2025, 11:53 AM

    While the litigation between Incyte Corporation and the company continues, the preliminary injunction is no longer in effect

    Read More
  • Sun Pharma launches Fexuprazan tablets 40 mg in India
    7th Apr 2025, 10:47 AM

    The company has obtained rights from Daewoong Pharmaceutical Co, Korea to manufacture and commercialise FEXUCLUE (Fexuprazan) in India

    Read More
  • Sun Pharma’s arm recalls 9,840 bottles of Morphine Sulfate extended-release tablets in US
    17th Mar 2025, 16:20 PM

    The company initiated the Class II nationwide (US) recall on February 6, 2025

    Read More
  • Sun Pharma to acquire Checkpoint Therapeutics
    10th Mar 2025, 10:17 AM

    The transaction is expected to be completed in the second calendar quarter of 2025

    Read More
  • Sun Pharmaceutical included in S&P Global Sustainability Yearbook 2025
    17th Feb 2025, 15:23 PM

    Within respective industries, this Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

    Read More
  • Sun Pharmaceutical reports 14% surge in Q3 consolidated net profit
    31st Jan 2025, 17:18 PM

    Total consolidated income of the company increased by 11.96% at Rs 14141.08 crore for Q3FY25

    Read More
  • Sun Pharma Inds. - Quarterly Results
    31st Jan 2025, 15:12 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.